Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $3,211 | 2 | 93.6% |
| Food and Beverage | $128.77 | 2 | 3.8% |
| Education | $90.32 | 3 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,211 | 2 | $0 (2023) |
| Celgene Corporation | $102.88 | 1 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $90.32 | 3 | $0 (2019) |
| Genentech USA, Inc. | $25.89 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,314 | 3 | E.R. Squibb & Sons, L.L.C. ($3,211) |
| 2022 | $25.89 | 1 | Genentech USA, Inc. ($25.89) |
| 2019 | $28.32 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($28.32) |
| 2018 | $62.00 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($62.00) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $102.88 | General |
| Category: Hematology | ||||||
| 07/24/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,729.00 | General |
| 02/06/2023 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Consulting Fee | Cash or cash equivalent | $1,482.00 | General |
| Category: Oncology | ||||||
| 09/27/2022 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ, ROZLYTREK | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: BioOncology | ||||||
| 05/08/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Education | In-kind items and services | $14.16 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Education | In-kind items and services | $14.16 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Education | In-kind items and services | $62.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,446 | 101,056 | $3.9M | $1.2M |
| 2022 | 27 | 1,721 | 101,173 | $1.6M | $404,875 |
| 2021 | 34 | 2,223 | 92,389 | $1.7M | $446,371 |
| 2020 | 24 | 1,316 | 30,031 | $1.3M | $319,477 |
All Medicare Procedures & Services
113 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 21,400 | $2.4M | $839,641 | 35.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 233 | 962 | $175,084 | $87,198 | 49.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 32 | 3,360 | $134,400 | $61,116 | 45.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 74 | 2,267 | $312,846 | $49,668 | 15.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 42 | 390 | $242,580 | $39,091 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 445 | $51,620 | $30,565 | 59.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 63 | 516 | $142,416 | $24,610 | 17.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 13 | 31,110 | $62,220 | $12,173 | 19.6% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 79 | 911 | $60,126 | $8,772 | 14.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 185 | 1,037 | $35,292 | $7,702 | 21.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 33 | 394 | $34,672 | $6,130 | 17.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $15,100 | $5,315 | 35.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 31 | 171 | $24,111 | $3,735 | 15.5% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 52 | 86 | $13,760 | $3,676 | 26.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 15 | 59 | $17,877 | $2,931 | 16.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 12 | 14 | $2,730 | $2,190 | 80.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 59 | 186 | $15,624 | $2,022 | 12.9% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 12 | 45 | $11,475 | $1,921 | 16.7% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 79 | 954 | $18,126 | $1,914 | 10.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 33 | 33 | $7,425 | $1,885 | 25.4% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 18 | 8,850 | $35,400 | $1,197 | 3.4% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 18 | 6,900 | $13,800 | $1,086 | 7.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 12 | 70 | $6,650 | $837.66 | 12.6% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 50 | 10,492 | $62,952 | $773.99 | 1.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 41 | 8,268 | $8,268 | $772.84 | 9.3% |
About Dr. Elham Abbasi-Hafshejani, M.D
Dr. Elham Abbasi-Hafshejani, M.D is a Hematology & Oncology healthcare provider based in The Woodlands, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1306856513.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elham Abbasi-Hafshejani, M.D has received a total of $3,430 in payments from pharmaceutical and medical device companies, with $3,314 received in 2023. These payments were reported across 7 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($3,211).
As a Medicare-enrolled provider, Abbasi-Hafshejani has provided services to 6,706 Medicare beneficiaries, totaling 324,649 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 113 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location The Woodlands, TX
- Active Since 08/09/2006
- Last Updated 11/23/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1306856513
Products in Payments
- SPRYCEL (Drug) $1,482
- REBLOZYL (Biological) $102.88
- GILOTRIF (Drug) $90.32
- Alecensa (Biological) $25.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in The Woodlands
Dr. Mohsen Arani, Md, MD
Hematology & Oncology — Payments: $138,400
Thomas Guerrero-Garcia, M.d, M.D
Hematology & Oncology — Payments: $3,012
Elim Kuo
Hematology & Oncology — Payments: $1,129
Dr. Angela Coscio, Md, MD
Hematology & Oncology — Payments: $876.31
Gurdeep Sethi, Md, MD
Hematology & Oncology